bacilli
enterobacteriacea
pseudomonada
caus
cap
patient
previou
antimicrobi
treatment
pulmonari
comorbid
frequenc
caus
mycobacterium
tuberculosi
c
psittaci
psittacosi
c
burnetii
q
fever
francisella
tularensi
tularaemia
endem
fungi
histoplasmosi
coccidioidomycosi
blastomycosi
vari
epidemiolog
set
tabl
show
caus
cap
adult
hospit
report
worker
sever
prospect
studi
sever
worldwid
locat
use
comprehens
diagnost
approach
incid
specif
pathogen
vari
accord
complet
test
specif
diagnost
criteria
ie
definit
vs
presumpt
diagnosi
tabl
collect
pneumonia
frequent
isol
organ
highest
incid
pathogen
report
studi
includ
detect
urinari
antigen
test
rel
pathogen
pneumonia
c
pneumonia
l
pneumophila
also
common
organ
along
chlamydia
spp
c
burnetii
often
refer
atyp
label
contend
scientif
merit
nevertheless
term
remain
popular
clinician
widespread
use
recent
scientif
report
atyp
pathogen
often
identifi
clinic
practic
howev
except
l
pneumophila
specif
rapid
standardis
test
detect
frequenc
pathogen
probabl
underreport
communityacquir
pneumonia
thoma
seminar
reli
articl
retriev
search
medlin
identifi
pertin
articl
cap
publish
sinc
consensu
statement
guidelin
manag
cap
adult
prefer
given
publish
articl
evidencedbas
extens
review
grade
studi
literatur
support
expert
opinion
seminar
review
import
featur
manag
issu
communityacquir
pneumonia
cap
especi
relev
immunocompet
adult
light
new
inform
caus
clinic
cours
diagnost
test
treatment
prevent
streptococcu
pneumonia
remain
import
pathogen
howev
emerg
resist
organ
antimicrobi
agent
affect
empir
treatment
cap
atyp
pathogen
quit
commonli
identifi
sever
prospect
studi
clinic
signific
pathogen
except
legionella
spp
clear
partli
lack
rapid
standardis
test
diagnost
evalu
cap
import
appropri
assess
sever
ill
establish
caus
agent
diseas
better
rapid
diagnost
method
develop
patient
treat
empir
antimicrobi
continu
mainstay
treatment
decis
specif
agent
guid
sever
consider
includ
spectrum
activ
pharmacokinet
pharmacodynam
principl
sever
factor
shown
associ
benefici
clinic
outcom
patient
cap
factor
includ
administr
antimicrobi
time
manner
choic
antibiot
therapi
use
critic
pneumonia
pathway
appropri
use
vaccin
pneumococc
diseas
influenza
encourag
sever
guidelin
manag
cap
recent
publish
recommend
review
proport
case
recent
studi
defin
caus
rang
contrast
observ
studi
assess
realworld
practic
sever
centr
usa
outpati
quarter
inpati
cap
caus
diseas
defin
studi
consecut
patient
cap
ruizgonzal
colleagu
use
microbiolog
analysi
pcr
test
respiratori
pathogen
lung
aspir
specimen
obtain
transthorac
needl
aspir
result
show
use
test
increas
proport
case
cap
caus
could
establish
report
convent
testsi
sputum
blood
cultur
serolog
testswer
use
result
also
chang
rank
pathogen
establish
convent
test
pneumonia
c
pneumonia
pneumonia
pneumonia
pneumonia
c
pneumonia
importantli
pneumonia
repres
one
third
caus
document
convent
test
legionella
spp
still
common
caus
sever
cap
review
nine
studi
cap
result
admiss
intens
care
unit
seven
europ
one
usa
south
africa
note
legionella
spp
second
commonli
identifi
pathogen
pneumonia
often
detect
aerob
gramneg
bacilli
h
influenza
aureu
also
identifi
although
case
could
judg
definit
ie
confirm
bacteraemia
isol
pleural
fluid
lung
tissu
intern
collabor
survey
patient
cultureposit
legionellosi
isol
serogroup
l
pneumophila
account
total
l
pneumophila
serogroup
account
isol
america
europ
australia
new
zealand
l
longbeacha
account
case
common
pathogen
identifi
recent
studi
mild
ie
ambulatori
patient
cap
pneumonia
pneumonia
chlamydia
spp
virus
mostli
influenza
viru
mycoplasma
spp
common
patient
younger
year
without
import
comorbid
condit
abnorm
vital
sign
wherea
pneumonia
common
pathogen
older
patient
signific
underli
diseas
awar
like
caus
cap
differ
set
import
allow
start
appropri
antimicrobi
treatment
tabl
show
common
pathogen
associ
cap
deriv
collect
result
variou
studi
sever
ill
judg
site
care
outpati
vs
inpati
although
object
confirm
often
difficult
multipl
organ
infect
patient
concurr
sequenti
caus
cap
exampl
influenza
c
pneumonia
infect
might
follow
secondari
infect
pneumonia
one
studi
patient
admit
serolog
diagnos
c
pneumonia
pneumonia
patient
infect
pathogen
common
copathogen
pneumonia
incid
mix
infect
vari
diagnost
method
bc
sc
lc
bc
sc
vc
ser
bc
sc
mpc
bc
sc
lc
bc
sc
ser
bc
sc
lua
bc
sc
lc
bc
sc
nac
ser
lua
clc
lc
lua
vc
lua
pcr
npva
aspir
data
total
proport
case
ie
definit
presumpt
diagnos
number
parenthes
proport
definit
diagnos
definit
diagnosi
assign
one
follow
criteria
cap
pathogen
cultur
normal
steril
site
noncommens
organ
eg
mycobacterium
tuberculosi
legionella
spp
identifi
site
posit
urinari
antigen
posit
pcr
test
pair
serolog
test
reveal
signific
increas
antibodi
titr
presumpt
diagnosi
assign
growth
pathogen
sputum
cultur
accompani
gram
stain
show
compat
organ
one
high
serum
antibodi
titr
note
pathogen
although
ruizgonzal
specif
defin
statu
diagnost
criteria
definit
presumpt
method
use
accept
repres
definit
diagnosi
criteria
studi
ambulatori
patient
cap
median
time
resolut
fever
day
day
myalgia
day
dyspnoea
day
cough
fatigu
symptom
last
even
longer
serious
ill
patient
fine
colleagu
note
patient
least
one
persist
pneumoniarel
symptom
day
patient
inform
symptom
last
long
allow
better
awar
ill
expect
clinic
cours
death
rate
associ
cap
chang
greatli
past
two
decadesin
part
increas
number
patient
risk
diseas
elderli
peopl
patient
multipl
comorbid
condit
prospect
studi
prognost
factor
cap
caus
bacteraem
pneumococc
diseas
five
countri
death
rate
rang
canada
usa
spain
uk
sweden
independ
predictor
death
age
greater
year
resid
nurs
home
presenc
chronic
lung
diseas
high
acut
physiolog
chronic
health
evalu
apach
score
need
mechan
ventil
diseas
sever
frequenc
underli
condit
factor
affect
outcom
mortensen
colleagu
note
half
death
patient
cap
attribut
worsen
preexist
condit
diagnost
evalu
patient
symptom
suggest
pneumonia
import
sever
reason
accur
diagnosi
cap
appropri
assess
sever
ill
appropri
use
microbiolog
analys
establish
caus
ill
adult
patient
immunocompet
assess
pneumonia
present
symptom
includ
cough
sputum
product
labour
breath
includ
alter
breath
sound
rale
fever
symptom
nonspecif
might
also
present
patient
upper
respiratorytract
infect
lower
respiratorytract
infect
acut
bronchiti
chronic
bronchiti
noninfecti
diseaseseg
reactiv
airway
diseas
atelectasi
congest
heart
failur
vascul
pulmonari
embol
malign
diseas
although
guidelin
vari
respect
emphasi
place
obtain
chest
radiograph
ambulatori
patient
studi
usual
necessari
establish
diagnosi
cap
differenti
respiratori
ill
cap
diagnosi
import
ensur
appropri
use
antimicrobi
agent
especi
sinc
case
upper
respiratorytract
infect
acut
bronchiti
viral
origin
merit
treatment
antibacteri
agent
spiral
ct
scan
much
sensit
detect
pulmonari
infiltr
patient
admit
cap
clinic
signific
find
unclear
ill
sever
site
care
key
decis
clinician
whether
admit
patient
cap
hospit
gener
consensu
patient
safe
treat
outpati
howev
select
patient
admit
special
requir
need
close
observ
respiratori
support
intraven
antibiot
concern
decis
whether
patient
admit
might
effect
extent
diagnost
test
well
choic
empir
antimicrobi
treament
advantag
admit
patient
cap
great
includ
decreas
cost
patient
prefer
avoid
iatrogen
complic
hospit
elderli
patient
particular
reduct
immobilis
time
ie
time
hospit
bed
facilit
better
convalesc
decis
admit
patient
cap
depend
mani
variabl
includ
sever
ill
associ
diseas
adequaci
home
support
probabl
adher
treatment
recognis
risk
factor
increas
mortal
patient
cap
includ
extrem
age
comorbid
ill
malign
diseas
congest
heart
failur
coronari
arteri
diseas
alcohol
abnorm
vital
sign
sever
laboratori
radiograph
find
admiss
decis
reli
clinician
judgment
howev
prognost
score
rule
develop
provid
support
decis
pneumonia
sever
index
score
pneumonia
predict
rule
develop
studi
pneumonia
patient
outcom
research
team
port
predict
rule
stratifi
patient
one
five
categori
point
system
base
sever
variabl
initi
evalu
three
factor
age
presenc
comorbid
condit
vital
sign
mental
statu
process
valid
method
identifi
patient
risk
death
low
risk
class
iiii
intermedi
class
iv
high
class
v
also
effect
method
triag
patient
particular
identifi
lowrisk
patient
safe
treat
outpati
subsequ
recommend
pneumonia
port
calcul
sever
index
score
patient
first
assess
preexist
condit
might
compromis
safeti
home
care
includ
haemodynam
instabl
activ
coexist
condit
would
necessit
admiss
acut
hypoxaemia
social
psychiatr
problem
compromis
home
care
inabl
take
oral
medic
contrast
british
thorac
societi
guidelin
recommend
assess
sever
base
presenc
advers
prognost
featur
advers
featur
includ
age
greater
year
coexist
diseas
four
addit
specif
core
featur
rememb
acronym
curb
mental
confus
elev
urea
nitrogen
respiratori
rate
greater
equal
breath
per
min
low
blood
pressur
addit
advers
prognost
featur
includ
hypoxaemia
bilater
multilobar
pulmonari
infiltr
chest
radiograph
patient
none
featur
list
low
risk
death
usual
requir
inpati
care
wherea
display
two
core
advers
prognost
featur
admit
score
method
base
british
thorac
societi
assess
develop
system
assess
use
compil
data
three
prospect
studi
cap
done
uk
new
zealand
netherland
six
point
score
one
point
confus
urea
mmoll
respiratori
rate
low
blood
pressur
age
year
enabl
patient
stratifi
accord
risk
death
score
increas
risk
death
simpl
score
system
use
stratifi
patient
cap
differ
group
manag
purpos
predict
rule
might
oversimplifi
interpret
import
variabl
therefor
score
system
seminar
lancet
vol
decemb
wwwthelancetcom
guidelin
meant
contribut
rather
supersed
clinician
judgment
addit
limit
sever
ill
score
system
includ
potenti
overemphasi
age
percept
healthcar
worker
system
practic
everyday
routin
patient
manag
univers
accept
criteria
sever
cap
requir
admiss
intens
care
unit
one
set
variabl
propos
reliabl
predictor
defin
sever
cap
presenc
two
three
possibl
minor
criteria
systol
bp
mm
hg
multilobar
diseas
pao
fio
one
two
major
criteria
need
mechan
ventil
septic
shock
howev
assess
pneumonia
port
studi
group
note
criteria
modest
predict
valu
identif
caus
agent
use
diagnost
studi
establish
caus
agent
cap
controversi
rapid
easili
done
accur
costeffect
method
allow
immedi
result
patient
point
servic
ie
initi
assess
clinician
offic
acutecar
set
nevertheless
good
rational
establish
caus
agent
diseas
allow
select
antibiot
permit
optimum
select
agent
specif
pathogen
limit
misus
antibiot
consequ
identifi
pathogen
associ
notifi
diseas
legionnair
diseas
tuberculosi
despit
good
reason
absenc
solid
document
benefit
respect
establish
caus
agent
routin
microbiolog
test
recommend
guidelin
patient
manag
commun
howev
patient
purul
sputum
reason
send
sampl
laboratori
gram
stain
cultur
basi
inform
could
use
direct
specif
treatment
patient
fail
respond
initi
empir
treatment
investig
recommend
patient
requir
admiss
includ
blood
cultur
sputum
gram
stain
cultur
thoracentesi
pleural
fluid
present
patient
cap
posit
blood
cultur
commonli
associ
sever
ill
although
use
blood
cultur
patient
admit
hospit
question
investig
one
studi
note
result
blood
cultur
obtain
within
h
admiss
surviv
rate
improv
yield
clinic
use
inform
greater
cultur
specimen
collect
antibiot
administ
valu
routin
sputum
gram
stain
cultur
long
debat
test
limit
fact
mani
patient
produc
good
specimen
patient
often
receiv
antimicrobi
agent
assess
mani
specimen
yield
inconclus
result
valid
gram
stain
relat
directli
experi
interpret
inde
discrep
find
sputum
gram
stain
presum
explain
qualiti
specimen
technic
expertis
stringent
criteria
appli
although
sensit
drop
specif
pneumococc
pneumonia
approach
sputum
cultur
pathogen
ie
legionella
spp
fungi
virus
mycobacterium
spp
consid
identifi
unusu
pathogen
notifi
diseas
howev
earli
administr
treatment
import
outcom
cap
attempt
obtain
expector
sputum
never
delay
prompt
start
antimicrobi
treatment
test
might
use
patient
admit
hospit
includ
urinari
antigen
assay
legionella
spp
pneumonia
direct
stain
ie
acidfast
detect
mycobacteri
infect
patient
highrisk
categori
tuberculosi
urin
antigen
assay
l
pneumophila
serogroup
lgua
pneumococcu
spua
done
easili
rapidli
lgua
sensit
specif
greater
infect
caus
serogroup
especi
use
usa
europ
sinc
isol
serogroup
sinc
legionella
spp
common
caus
sever
cap
test
routin
consid
patient
requir
admiss
intens
care
unit
assay
approv
food
drug
administr
fda
pneumococc
urinari
antigen
assess
sever
studi
sensit
defin
invas
pneumococc
diseas
adult
specif
close
one
largest
publish
studi
date
gutierrez
colleagu
use
assay
concentr
urin
sampl
obtain
adult
cap
pneumococc
antigen
detect
patient
proven
pneumococc
pneumonia
patient
pneumonia
pathogen
identifi
antigen
detect
suggest
import
proport
case
present
undiagnos
standard
test
identifi
assay
howev
sampl
patient
pneumonia
caus
agent
posit
indic
potenti
problem
specif
mani
rapid
diagnost
test
nucleic
acid
amplif
test
ie
pcr
assay
still
earli
stage
develop
commonli
avail
suffici
accur
role
new
tool
investig
yet
routin
use
howev
could
offer
potenti
rapid
diagnosi
shown
use
clinic
situat
serolog
test
usual
help
earli
manag
cap
sinc
acut
convalesc
concentr
need
ascrib
caus
diseas
specif
pathogen
percutan
transthorac
needl
aspir
ptna
advoc
valuabl
safe
method
increas
chanc
establish
caus
agent
diseas
nevertheless
ptna
invas
test
includ
bronchoscopi
biopsi
routin
recommend
assess
patient
cap
clinic
set
might
warrant
use
test
includ
pneumonia
immunocompromis
host
suspect
tuberculosi
absenc
product
cough
select
case
chronic
pneumonia
pneumonia
associ
suspect
neoplasm
foreign
bodi
suspect
pneumocysti
carinii
pneumonia
case
intub
requir
suspect
condit
necessit
lung
biopsi
antimicrobi
mainstay
treatment
patient
cap
decis
antimicrobi
treatment
guid
factor
spectrum
activ
pharmacokinet
efficaci
safeti
profil
cost
whether
specif
pathogen
identifi
ie
empir
vs
pathogendirect
treatment
emerg
resist
respiratori
pathogen
especi
drugresist
strain
pneumonia
becom
import
concern
complic
initi
empir
manag
cap
surveil
studi
indic
preval
drug
resist
pneumonia
continu
increas
worldwid
two
recent
multin
studi
worldwid
preval
penicillinresist
macrolideresist
pneumonia
rang
respect
domin
factor
emerg
drug
resist
pneumonia
one
us
studi
humantohuman
spread
clonal
group
harbour
resist
determin
multipl
class
antibiot
includ
cephalosporin
macrolid
doxycyclin
trimethoprimsulfamethoxazol
despit
rapid
increas
preval
drug
resist
pneumonia
clinic
relev
outcom
cap
remain
controversi
depend
class
antimicrobi
agent
consid
studi
suggest
current
level
lactam
resist
usual
result
treatment
failur
patient
cap
present
breakpoint
pneumonia
suscept
penicillin
gml
suscept
gml
intermedi
suscept
gml
resist
relev
meninig
reliabl
predict
clinic
outcom
cap
basi
establish
pharmacokinet
pharmacodynam
principl
adequ
drug
concentr
serum
tissu
achiev
appropri
dose
parenter
lactam
oral
amoxicillin
treat
effect
mani
pneumococc
strain
thought
nonsuscept
penicillin
present
criteria
furthermor
analysi
nine
control
trial
highdos
oral
formul
amoxicillinclavulan
note
good
clinic
respons
respiratori
infect
mostli
outpati
caus
pneumonia
penicillin
minim
inhibitori
concentr
mic
gml
although
studi
shown
advers
effect
lactam
resist
outcom
pneumococc
pneumonia
clinician
remain
concern
clinic
failur
becom
frequent
proport
resist
strain
mic
increas
moreov
control
studi
pneumococc
bacteraemia
feikin
colleagu
note
increas
risk
death
patient
highlevel
resist
penicillin
mic
gml
metlay
colleagu
show
increas
risk
suppur
complic
nonsuscept
infect
risk
factor
penicillinresist
pneumonia
identifi
ie
age
year
year
lactam
treatment
within
month
alcohol
medic
comorbid
immunosuppress
ill
treatment
exposur
child
daycar
centr
clinic
relev
macrolid
resist
pneumonia
might
depend
type
resist
express
particular
strain
common
mechan
resist
includ
methyl
ribosom
target
encod
erm
gene
efflux
macrolid
cell
membran
protein
transport
encod
mef
gene
pneumonia
strain
mef
resist
lower
level
mic
usual
gml
ermresist
strain
possibl
strain
especi
mic
gml
might
inhibit
suffici
high
concentr
macrolid
obtain
within
infect
tissu
could
aris
newer
macrolidesclarithromycin
azithromycin
howev
recent
evid
mic
strain
increas
could
affect
effect
macrolid
mefresist
strain
usual
suscept
clindamycin
ermresist
isol
mic
greater
gml
erythromycin
thought
highli
resist
macrolid
clindamycin
recent
report
failur
cap
treat
macrolid
rare
particularli
patient
low
risk
drugresist
strain
howev
sinc
anecdot
report
one
control
studi
document
failur
attribut
macrolideresist
pneumonia
patient
treat
oral
macrolid
subsequ
requir
admiss
pneumonia
bacteraemia
current
mefassoci
resist
predomin
north
america
ermassoci
resist
predomin
europ
common
japan
although
worldwid
preval
pneumococc
resist
newer
fluoroquinolon
levofloxacin
gatifloxacin
moxifloxacin
remain
low
fewer
case
countri
resist
increas
substanti
overal
preval
fluoroquinolon
resist
levofloxacin
gml
hong
kong
increas
dissemin
fluoroquinoloneresist
clone
treatment
failur
alreadi
report
often
patient
previous
treat
fluoroquinolon
risk
factor
levofloxacin
resist
identifi
previou
exposur
fluoroquinolon
resid
nurs
home
nosocomi
infect
chronic
obstruct
pulmonari
diseas
view
emerg
resist
pneumococcu
exist
drug
altern
agent
need
consid
although
glycopeptid
ie
vancomycin
teicoplanin
almost
certain
provid
antibiot
coverag
drug
resist
pneumonia
activ
key
respiratori
pathogen
ie
atyp
h
influenza
strong
reason
use
drug
need
fear
emerg
resist
organ
vancomycinresist
enterococci
vancomycin
resist
aureu
agent
effect
drugresist
pneumonia
includ
quinupristindalfopristin
linezolid
ketolid
focu
treatment
quinupristindalfopristin
linezolid
nosocomi
infect
especi
vancomycinresist
enterococci
macrolideresist
pneumonia
ketolid
telithromycin
first
market
novel
addit
macrolid
group
antibacteri
efficaci
key
respiratori
pathogen
includ
penicillinresist
erythromycinresist
strain
empir
antimicrobi
treatment
rapid
diagnost
method
improv
patient
treat
empir
although
author
propos
syndrom
approach
treatment
ie
count
predict
caus
agent
base
present
clinic
manifest
data
indic
present
clinic
featur
specif
enough
predict
reliabl
caus
agent
cap
thu
unless
specif
epidemiolog
factor
influenza
epidem
empir
approach
initi
therapi
usual
base
likelihood
one
key
pathogen
respons
diseas
specif
recommend
empir
therapi
cap
includ
recent
publish
guidelin
north
america
uk
japan
shown
tabl
sever
observ
studi
assess
effect
empir
antimicrobi
regimen
patient
outcom
although
limit
retrospect
design
studi
show
use
macrolid
part
initi
combin
treatment
usual
cephalosporin
agent
monotherapi
fluoroquinolon
seminar
lancet
vol
decemb
wwwthelancetcom
patient
requir
admiss
seem
associ
decreas
risk
death
shorter
hospit
stay
cephalosporin
alon
specif
caus
agent
infect
estalish
studi
howev
possibl
ad
coverag
atyp
pathogen
might
part
explain
observ
result
addit
retrospect
studi
suggest
benefit
combin
therapi
includ
macrolid
appli
cap
gener
also
cap
specif
associ
pneumonia
bacteraemia
possibl
coexist
atyp
pathogen
immunomodul
effect
macrolid
might
part
respons
find
howev
interpret
studi
subject
limit
inher
retrospect
studi
design
sinc
assess
empir
treatment
find
necessarili
applic
pathogendirect
treatment
usual
start
h
initi
therapi
recommend
empir
therapi
outpati
north
american
guidelin
variabl
recommend
macrolid
doxycyclin
antipneumococc
fluoroquinolon
eg
levofloxacin
gatifloxacin
moxifloxacin
combin
lactam
plu
macrolid
treatment
option
patient
mildli
ill
treat
outpati
gener
north
american
guidelin
recommend
macrolid
firstlin
treatment
outpati
comorbid
risk
factor
drugresist
pneumonia
rational
macrolid
provid
effect
therapi
common
bacteri
pathogen
patient
primarili
pneumonia
mostli
respons
macrolid
north
america
well
atyp
organ
especi
pneumonia
c
pneumonia
common
outpati
posit
macrolid
promin
firstlin
agent
north
american
guidelin
partli
base
presumpt
newer
macrolid
azithromycin
clarithromycin
effect
macrolideresist
pneumonia
strain
lowerlevel
resist
result
increas
drug
efflux
result
mic
often
less
gml
howev
recent
data
indic
mefmedi
resist
becom
associ
higher
mic
median
reason
consid
altern
treatment
ie
respiratori
fluoroquinolon
high
dose
amoxicillin
plu
macrolid
risk
factor
drugresist
pneumonia
present
center
diseas
control
prevent
cdc
statement
emphasis
fluoroquinolon
reserv
case
associ
failur
allergi
agent
document
drugresist
pneumonia
rational
widespread
use
would
lead
develop
fluoroquinolon
resist
respiratori
pathogen
well
pathogen
colonis
treat
patient
contrast
primari
agent
recommend
recent
publish
british
thorac
societi
guidelin
lactamsmostli
penicillinsand
macrolid
rational
agent
effect
pneumonia
given
high
dose
even
effect
strain
decreas
sensit
penicillin
sinc
macrolid
resist
europ
ermmedi
highlevel
resist
macrolid
regard
optimum
first
line
empir
agent
treat
pathogen
pneumonia
use
fluoroquinolon
plu
highdos
amoxicillin
gday
antipneumococc
fluoroquinolon
alon
clindamycin
amoxicillinclavulan
plu
macrolid
case
amoxicillin
use
structur
lung
diseas
concern
h
influenza
use
agent
antipseudomon
agent
piperacillin
activ
lactamas
produc
tazobactam
carbapenem
strain
cefepim
plu
antipseudomon
fluoroquinolon
high
dose
ciprofloxacin
levofloxacin
japanes
respiratori
specifi
mild
moder
specifi
sever
pneumonia
specifi
societi
pneumonia
consid
inpati
elderli
underli
ill
bacteri
pneumonia
suspect
younger
patient
without
underli
penicillin
type
lactamas
ill
inject
use
fluoroquinolon
inhibitor
oral
penicillin
type
elderli
underli
ill
pneumococc
activ
plu
altern
antipneum
fluoroquinolon
benzylpenicillin
altern
parenter
appropri
ampicillin
benzylpenicillin
plu
erythromycin
clarithromycin
altern
iv
levofloxacin
icu
intens
care
unit
drspdrug
resist
pneumonia
lactam
treatment
within
past
month
admiss
within
past
month
alcohol
immunesuppress
ill
includ
treatment
corticosteroid
medic
comorbid
exposur
child
daycar
centr
infecti
diseas
societi
canadian
thorac
societi
chronic
obstruct
pulmonari
diseas
use
macrolid
activ
lactamas
produc
h
influenza
ie
azithromycin
clarithromycin
levofloxacin
moxifloxacin
tabl
comparison
recommend
guidelin
empir
antimicrobi
therapi
communityacquir
pneumonia
adult
like
addit
british
statement
place
less
import
need
treat
atyp
pathogen
empir
ambulatori
patient
mild
diseas
rather
statement
suggest
sinc
pneumonia
exhibit
epidem
period
everi
year
chiefli
affect
younger
peopl
polici
initi
empir
treatment
aim
alway
cover
pathogen
unnecessari
two
approach
repres
north
american
british
thorac
societi
statement
differ
greater
emphasi
north
america
treat
routin
atyp
pathogen
fact
macrolideresist
pneumonia
europ
higher
level
resist
north
america
futur
studi
need
address
issu
whether
routin
treatment
abl
treat
atyp
pathogen
japanes
statement
advoc
initi
therapi
base
syndrom
approach
ie
macrolid
tetracyclin
like
atyp
pneumonia
penicillintyp
agent
bacteri
pneumonia
recommend
empir
therapi
inpati
north
american
guidelin
recommend
treatment
lactam
plu
macrolid
monotherapi
fluoroquinolon
patient
admit
gener
ward
part
result
show
regimen
associ
substanti
reduct
death
compar
note
cephalosporin
alon
recommend
british
thorac
societi
guidelin
similar
north
america
worker
two
recent
studi
europ
note
patient
admit
cap
success
treat
penicillin
alon
japanes
statement
stratifi
patient
basi
age
presenc
underli
ill
inject
fluoroquinolon
recommend
first
categori
combin
regimen
second
categori
patient
sever
cap
requir
admiss
intens
care
unit
guidelin
recommend
comprehens
antimicrobi
therapi
cover
pneumonia
includ
drugresist
pneumonia
legionella
spp
possibl
pseudomona
spp
australian
guidelin
advoc
empir
therapi
burkholderia
pseudomallei
patient
tropic
area
acknowledg
relev
local
pathogen
pathogendirect
therapi
treatment
option
obvious
simplifi
caus
agent
establish
strongli
suspect
tabl
diagnost
procedur
provid
identif
specif
caus
within
h
still
use
guid
continu
treatment
exampl
appropri
cultur
show
isol
penicillinsuscept
pneumonia
treatment
specifi
select
narrow
spectrum
agent
penicillin
amoxicillin
hope
reduc
select
pressur
resist
inform
often
avail
time
consider
patient
switch
parenter
oral
therapi
control
trial
specif
assess
optimum
durat
anitmicrobi
treatment
cap
decis
usual
base
caus
pathogen
respons
treatment
comorbid
ill
complic
data
avail
seem
reason
treat
bacteri
infect
caus
pneumonia
patient
afebril
h
randomis
clinic
trial
new
fluoroquinolon
newer
macrolid
shown
good
outcom
day
treatment
shorter
cours
could
even
possibl
use
agent
azithromycin
could
use
shorter
cours
treatment
ambulatori
patient
longer
halflif
tissu
mani
pathogen
clear
advantag
intraven
therapi
oral
therapi
howev
patient
admit
hospit
common
practic
begin
therapi
intraven
drug
chang
intraven
oral
therapi
patient
clinic
stabl
improv
abl
ingest
drug
associ
sever
econom
care
social
benefit
approach
shown
appropri
even
patient
pneumococc
bacteraemia
patient
safe
discharg
without
inhospit
observ
switch
oral
treatment
ideal
parenter
drug
given
oral
formul
adequ
bioavail
oral
formul
avail
oral
agent
similar
spectrum
activ
select
basi
vitro
predict
suscept
pattern
establish
probabl
pathogen
mani
studi
assess
process
carei
intervent
undertaken
assess
diagnos
treatwith
clinic
outcom
patient
tabl
metaanalysi
structur
review
publish
report
rhew
identifi
sever
qualiti
indic
judg
valid
basi
publish
evid
profession
consensu
associ
benefici
effect
outcom
elderli
patient
cap
indic
use
pneumococc
influenza
vaccin
prevent
cap
administr
antimicrobi
time
matter
within
h
arriv
hospit
advic
ceas
smoke
patient
smoke
drainag
pleural
empyema
convers
parenter
oral
antimicrobi
treatment
patient
improv
haemodynam
stabl
abl
take
oral
medic
use
appropri
discharg
criteria
ensur
patient
clinic
stabl
time
releas
hospit
wherea
studi
review
rhew
support
h
target
time
appropri
initi
antimicrobi
agent
recent
data
shown
start
therapi
within
h
associ
better
outcom
patient
need
admit
although
one
studi
cap
patient
admit
academ
medic
center
show
benefit
mani
indic
implement
pneumonia
practic
guidelin
promot
qualiti
indic
shown
mani
studi
associ
better
outcom
includ
reduc
risk
death
prevent
cap
despit
controversi
efficaci
polysaccharid
pneumococc
vaccin
ppv
vaccin
influenza
vaccin
recommend
current
guidelin
cdc
metaanalysi
trial
includ
patient
polysaccharid
pneumococc
vaccin
prevent
definit
pneumonia
mortal
allcaus
death
howev
vaccin
consist
effect
control
trial
elderli
patient
import
advanc
develop
licensur
pneumococc
conjug
vaccin
infant
reduc
seriou
pneumococc
infect
children
also
colonis
vaccin
strain
although
benefit
vaccin
yet
directli
proven
clinic
trial
adult
use
children
shown
reduc
rate
pneumococc
diseas
adult
reduct
probabl
due
decreas
transmiss
pneumococci
children
thu
could
provid
effect
method
reduc
diseas
caus
drugresist
strain
futur
challeng
cap
continu
repres
import
threat
patient
futur
number
patient
risk
elderli
peopl
comorbid
condit
increas
accucr
rapid
diagnost
method
defin
caus
pathogen
need
allow
specif
direct
therapi
specif
caus
pathogen
known
seem
reason
presum
patient
respond
better
antibiot
could
use
appropri
studi
assess
approach
need
although
discuss
review
greater
understand
pathogenesi
host
respons
lead
new
approach
treatment
complex
host
respons
reveal
therapeut
benefit
like
realis
optimum
approach
manag
need
constantli
reassess
new
inform
gener
hospit
admiss
admiss
lowrisk
patient
decis
associ
unnecessari
cost
diminish
patient
satisfact
time
initi
earlier
administr
associ
antibiot
improv
surviv
choic
antibiot
accord
guidelin
associ
therapi
better
outcom
switch
oral
therapi
associ
decreas
length
time
hospit
cost
appropri
even
strep
pneumonia
bacteraemia
discharg
criteria
associ
decreas
cost
readmiss
rate
use
critic
pathway
decreas
number
patient
admit
hospit
durat
admiss
mortal
modifi
meterski
tabl
select
cap
process
careoutcom
link
